Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

135.87USD
15 Dec 2017
Change (% chg)

$-0.17 (-0.12%)
Prev Close
$136.04
Open
$135.45
Day's High
$136.49
Day's Low
$133.50
Volume
285,330
Avg. Vol
92,217
52-wk High
$149.00
52-wk Low
$95.21

Chart for

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $2,981.39
Shares Outstanding(Mil.): 21.05
Dividend: --
Yield (%): --

Financials

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​

15 Nov 2017

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

* Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​

13 Nov 2017

BRIEF-Ligand Q3 adjusted earnings per share $0.69

* Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S

10 Nov 2017

BRIEF-Ligand to acquire Crystal Bioscience

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments

05 Oct 2017

BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

* Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

05 Sep 2017

BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody

* Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody discovered using the OmniAb technology

18 Aug 2017

BRIEF-Ligand Pharmaceuticals Q2 earnings per share $0.26

* Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S

08 Aug 2017

BRIEF-Ligand enters into commercial license, supply agreement with Amgen

* Ligand enters into commercial license and supply agreement with Amgen for rights to use captisol in the formulation of AMG 330

17 Jul 2017

BRIEF-Ligand partner Melinta Therapeutics says FDA approves antibiotic Baxdela

* ligand’s partner melinta therapeutics announces u.s. Fda approval of baxdela™ (delafloxacin) for acute bacterial skin and skin structure infections (absssi)

20 Jun 2017

Earnings vs. Estimates